Vigabatrin in the Treatment of Childhood Epilepsies: A Single‐Blind Placebo‐Controlled Study

Summary: Sixty‐one pediatric patients (12–229 months of age) with refractory epilepsy were treated with vigabatrin [γ‐vinyl GABA (GVG)] in a 16‐week, single‐blind, addon, placebo‐controlled trial. Twenty‐three patients (38%) showed a reduction of more than 50% in seizure frequency; 12 patients (20%) experienced a seizure increase; and the remaining 26 did not show significant differences between placebo and GVG treatment. Among the 16 patients who entered the long‐term phase after having experienced more than 50% decrease in seizure frequency, 14 continued with the same degree of improvement after 2–11 months of follow‐up (mean 7.7). GVG was particularly efficient in cryptogenic partial epilepsy. Conversely, nonprogressive myoclonic epilepsy tended to be aggravated. Agitation was the most commonly observed side effect, mainly at onset of therapy in mentally retarded patients, but was easily reversed by dose reduction. GVG is a promising drug in the treatment of refractory epilepsies of childhood.

[1]  W. Löscher,et al.  Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations , 1988, Epilepsy Research.

[2]  E. Mervaala,et al.  Effect of vigabatrin on epilepsy in mentally retarded patients , 1988, Neurology.

[3]  A. Ylinen,et al.  Double‐Blind Dose Reduction Study of Vigabatrin in Complex Partial Epilepsy , 1987, Epilepsia.

[4]  R. Michelucci,et al.  Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. , 1987, Archives of neurology.

[5]  R. Mattson,et al.  Vigabatrin for refractory complex partial seizures , 1987, Neurology.

[6]  P. Loiseau,et al.  Double‐Blind, Placebo‐Controlled Study of Vigabatrin (Gamma‐Vinyl GABA) in Drug‐Resistant Epilepsy , 1986, Epilepsia.

[7]  M. Dam,et al.  Long‐term study of gamma‐vinyl GABA in the treatment of epilepsy , 1985, Acta neurologica Scandinavica.

[8]  Proposal for Classification of Epilepsies and Epileptic Syndromes , 1985, Epilepsia.

[9]  M. Dam,et al.  γ‐Vinyl GABA: A double‐blind placebo‐controlled trial in partial epilepsy , 1985 .

[10]  B. Spilker,et al.  Validation of the Phenomenon of Regression of Seizure Frequency in Epilepsy , 1984, Epilepsia.

[11]  A. Sjoerdsma,et al.  Biochemical and clinical effects of γ‐vinyl GABA in patients with epilepsy , 1984, Neurology.

[12]  M. Dam,et al.  Gamma‐vinyl‐GABA: A single‐blind trial in patients with epilepsy , 1983, Acta neurologica Scandinavica.

[13]  C. Marescaux,et al.  Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid) , 1981 .

[14]  J. Engel,et al.  Effects of γ-acetylenic GABA and γ-vinyl GABA on metrazol-activated, and kindled seizures , 1979, Pharmacology Biochemistry and Behavior.

[15]  M. Palfreyman,et al.  The relationship between GABA concentrations in brain and cerebrospinal fluid , 1979, Brain Research.

[16]  H. Gastaut,et al.  Childhood Epileptic Encephalopathy with Diffuse Slow Spike‐Waves (otherwise known as “Petit Mal Variant”) or Lennox Syndrome , 1966, Epilepsia.

[17]  Jackson Mh.  Tubal patency tests. , 1947 .

[18]  J. Aicardi.  Myoclonic epilepsies of infancy and childhood. , 1986, Advances in neurology.

[19]  A. Richens,et al.  Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. , 1984, Lancet.

[20]  A. Sjoerdsma,et al.  Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. , 1984, Neurology.

[21]  B. Meldrum.  Pharmacology of GABA , 1982, Clinical neuropharmacology.

[22]  C. Marescaux,et al.  Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid). , 1981, Life sciences.

[23]  J. Engel,et al.  Effects of gamma-acetylenic GABA and gamma-vinyl GABA on metrazol-activated, and kindled seizures. , 1979, Pharmacology, biochemistry, and behavior.